Drugs in development could result in better hepatitis C treatment

07/21/2010 | New York Times (tiered subscription model), The

About two dozen pharmaceutical firms are pursuing medicines for hepatitis C that could make treatment far more effective and less taxing. The drugs, including Vertex Pharmaceuticals' telaprevir and Merck & Co.'s boceprevir, could give hope to an estimated 300,000 hepatitis C patients who have not responded to existing treatment.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT